ROBERT E. VESTAL, M.D.; BARRY H. RUMACK, M.D.
To the editor: Glutethimide (Doriden®1) may produce physical dependence and addiction, with the associated abstinence syndrome on withdrawal (1). Smith and Wesson (2) proposed using phenobarbital, a long-acting barbiturate, as a substitute for the primary addicting agent, when treating withdrawal from various nonopiate drugs. In this case we used phenobarbital to treat the glutethimide abstinence syndrome.
A 28-year-old man was admitted to the hospital because of chronic glutethimide abuse. His average daily dose for about 2½ years was 5 g/day, but he had used doses of 13.5 g/day. During the preceding 5 weeks the patient had gradually reduced his daily
VESTAL RE, RUMACK BH. Glutethimide Dependence: Phenobarbital Treatment. Ann Intern Med. ;80:670. doi: 10.7326/0003-4819-80-5-670_1
Download citation file:
Published: Ann Intern Med. 1974;80(5):670.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use